Investment
Features
FeesSafety
Academy
More
Pluang+

DMC Global to release Q3 2026 financial results on October 27 after market close

Company Fundamentals
14 Oct 2026
Not Specified
View Source
Neutral
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with insights into its performance. DMC Global operates in specialized manufacturing sectors including architectural products, energy, and industrial infrastructure. This report will be closely watched as it reflects the company’s recent business developments and financial health.

DMC Global's upcoming third quarter financial results are scheduled for October 27, 2026. For readers following Industrials-sector stocks, here is Pluang's market snapshot as of Oct 14, 2026 17:01 WIB: out of 136 priced stocks, 89 rose and 41 fell. Notable movers include Frontline Plc Ordinary Shares at USD 60.27 with a 1-day change of +2.09% and a Pluang order activity of 91% Buy, Trane Technologies plc at USD 488.00 with a +2.09% change, and Bloom Energy at USD 258.64 with a -1.83% change and a typical hold time of 9 days on Pluang.

More News

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
21 minutes ago
Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
21 minutes ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
1 hour ago
Global anthracite market to reach $16.8B by 2035, driven by steel and water filtration demand.

Global anthracite market to reach $16.8B by 2035, driven by steel and water filtration demand.

The global anthracite market, valued at $11.9 billion in 2025, is projected to grow to $16.8 billion by 2035 with a 3.5% CAGR. Growth is fueled by rising demand in steel production, water filtration, and advanced industrial uses due to anthracite's h...

Market News
Bullish
1 hour ago
Intel stock nearly triples in 2026, but a 2016 $10K investment still lags behind the S&P 500.

Intel stock nearly triples in 2026, but a 2016 $10K investment still lags behind the S&P 500.

Intel's stock price has surged nearly threefold in 2026, reflecting strong market performance this year. However, an investment of $10,000 made in Intel shares back in 2016 would still have underperformed compared to simply investing in the S&P 500 i...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App